Supernus Pharmaceuticals (SUPN) Income from Discontinued Operations (2011)
Supernus Pharmaceuticals' (SUPN) quarterly Income from Discontinued Operations came in at $76.4 million in Q4 2011, up 18219.9% quarter-over-quarter from $417000.0 in Q3 2011.
Powered by 
Analysis
Supernus Pharmaceuticals (SUPN) Income from Discontinued Operations (2011) Analysis & Trends
Supernus Pharmaceuticals (SUPN) has reported Income from Discontinued Operations for 1 consecutive years, with $76.4 million the latest figure, recorded in Q4 2011.
- On a quarterly basis, Income from Discontinued Operations changed N/A year-over-year to $76.4 million in Q4 2011; TTM through Dec 2011 was $77.0 million, a N/A change from a year earlier, with the FY2011 full-year figure at $77.0 million, up 12488.24% from the prior year.
- Income from Discontinued Operations was $76.4 million for Q4 2011 at Supernus Pharmaceuticals, up from $417000.0 in the prior quarter.
- Over five years, Income from Discontinued Operations peaked at $76.4 million in Q4 2011 and troughed at -$1.3 million in Q1 2011.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 642.70 Bn | 621.95 Bn | 17.26 Bn | - |
| 2 | AbbVie | 440.80 Bn | 434.23 Bn | 12.70 Bn | - |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.37 Bn | 258.68 Bn | 11.24 Bn | - |
| 5 | Pfizer | 158.89 Bn | 147.19 Bn | 10.94 Bn | 8.00 Mn |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 44.38 Bn | 44.38 Bn | - | - |
| 8 | Incyte | 25.28 Bn | 20.74 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.46 Bn | 18.80 Bn | 683.80 Mn | - |
| 10 | Supernus Pharmaceuticals | 2.42 Bn | 2.05 Bn | 185.39 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2011 | 76.39 Mn |
| Sep 30, 2011 | 417,000.00 |
| Jun 30, 2011 | 1.56 Mn |
| Mar 31, 2011 | -1.33 Mn |